Lingke Pharmaceutical (Hangzhou) Co., Ltd.
 浙ICP备19010130号      Powered by www.300.cn 

FOCUSED ON THE CURE

 

Lynk Pharmaceuticals was founded by veteran drug hunters from Pfizer, Merck and Johnson & Johnson with more than 7 decades of
rich experiences in drug discovery collectively. Driven
 by a higher
purpose, Lynk Pharmaceuticals aims at growing into a market
leader for developing
innovative therapies to address unmet medical needs in
Asian Pacific and with a global reach

......

2018

Founded in

2000

160

square meters

+

+

Area covered

 people

specialized persons

Leadership                >

Investors                    >

Research                   >

Partnering              >

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

Release time:
2022-03-18 18:06
On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

Release time:
2022-03-02 18:18
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

Release time:
2022-01-19 20:15
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

Founder and CEO: Dr. Wan Zhaokui: Ph. D. of Boston University
and post-doctoral of Harvard

NEWS CENTER